{
    "clinical_study": {
        "@rank": "50286", 
        "arm_group": [
            {
                "arm_group_label": "Lurasidone 40 mg", 
                "arm_group_type": "Experimental", 
                "description": "Lurasidone 40 mg once daily"
            }, 
            {
                "arm_group_label": "Lurasidone 80 mg", 
                "arm_group_type": "Experimental", 
                "description": "Lurasidone 80 mg once daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 40 or 80 mg once daily"
            }
        ], 
        "brief_summary": {
            "textblock": "Efficacy and Safety study of Lurasidone in pediatric patients."
        }, 
        "brief_title": "Pediatric Schizophrenia Efficacy and Safety Study", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "detailed_description": {
            "textblock": "To evaluate the efficacy of lurasidone (40 mg/day and 80 mg/day) compared with placebo in\n      adolescent subjects with schizophrenia (diagnosed by Diagnostic and Statistical Manual of\n      Mental Disorders, 4th Ed., Text Revision [DSM-IV-TR] criteria) as measured by the change\n      from Baseline in the Positive and Negative Syndrome Scale (PANSS) total score at Week 6."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent from parent(s) or legal guardian(s) with sufficient\n             intellectual capacity to understand the study and support subjects' adherence to the\n             study procedures must be obtained for subjects who are not emancipated. In accordance\n             with Institutional Review Board (IRB) requirements, the subject will complete an\n             informed assent prior to study participation.\n\n          -  Male or female subjects 13 to 17 years of age, inclusive, at the time of consent.\n\n          -  DSM-IV-TR axis I primary diagnosis of schizophrenia (including disorganized (295.10),\n             paranoid (295.30), undifferentiated (295.90) subtypes) and confirmation of the\n             schizophrenia diagnosis by an adequately trained clinician at the time of screening,\n             by means of the Schedule for Affective Disorders and Schizophrenia for School-age\n             Children (K-SADS-PL).\n\n          -  PANSS total score \u2265 70 at screening and Baseline.\n\n          -  CGI-S \u2265 4 at screening and Baseline.\n\n          -  Within 5th to 95th percentile for gender specific weight-for-age and height-for-age\n             Growth Charts from National Center for Health Statistics.\n\n          -  In good physical health on the basis of medical history, physical examination, and\n             laboratory screening.\n\n          -  Females who participate in this study:\n\n        are unable to become pregnant (eg, premenarchal, surgically sterile, etc.); -OR-\n\n        practices true abstinence (consistent with lifestyle) and must agree to remain abstinent\n        from signing informed consent to at least 30 days after the last dose of study drug has\n        been taken;\n\n        -OR-\n\n        are sexually active and willing to use a medically effective method of birth control\n        (e.g., male using condom and female using condom, diaphragm, contraceptive sponge,\n        spermicide, contraceptive pill, or intrauterine device) from signing informed consent to\n        at least 7 days after the last dose of study drug has been taken.\n\n          -  Males must be willing to remain sexually abstinent (consistent with lifestyle) or use\n             an effective method of birth control (eg, male using condom and female using condom,\n             diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine\n             device) from signing informed consent to at least 30 days after the last dose of\n             study drug has been taken.\n\n          -  In the judgement of the clinician, the subject has an acute exacerbation of psychotic\n             symptoms (no longer than 2 months in duration) and marked deterioration of function\n             from baseline (by history) or, the subject has been hospitalized for the purpose of\n             treating an acute psychotic exacerbation for 2 consecutive weeks or less immediately\n             before screening.\n\n          -  In the judgment of the investigator, the subject is able to swallow the size and\n             number of study drug tablets specified per protocol.\n\n          -  Willing and able to adhere to protocol-specified meal requirements during dosing.\n\n        Exclusion Criteria:\n\n          -  Has an Axis I or Axis II diagnosis other than schizophrenia that has been the primary\n             focus of treatment within 3 months of screening.\n\n          -  Has a history or current diagnosis of mental retardation, neuroleptic malignant\n             syndrome, or any neurologic disorder, or severe head trauma.\n\n          -  Lifetime history of human immunodeficiency virus (HIV) positive or acquired immune\n             deficiency syndrome (AIDS), or history of Hepatitis B or C.\n\n          -  Any of the following:\n\n        Documented history of chromosomal disorder with developmental impairment (ie, trisomy\n        chromosome 21; 22q11 deletion syndrome).\n\n        Evidence of any chronic organic disease of the CNS such as tumors, inflammation, active\n        seizure disorder, vascular disorder, potential CNS related disorders that might occur in\n        childhood- eg, Duchenne Muscular dystrophy, myasthenia gravis, or other neurologic or\n        serious neuromuscular disorders. In addition, subjects must not have a history of\n        persistent neurological symptoms attributable to serious head injury. Past history of\n        febrile seizure, drug-induced seizure, or alcohol withdrawal seizure is not exclusionary.\n\n          -  PANSS total scores \u2265 120 at screening or Baseline.\n\n          -  Exhibits evidence of moderate or severe extrapyramidal symptoms, dystonia, tardive\n             dyskinesia, or any other moderate or severe movement disorder. Severity to be\n             determined by the investigator.\n\n          -  Lifetime history of electroconvulsive therapy (ECT).\n\n          -  Resistant to antipsychotic treatment based on at least two different prior adequate\n             trials (ie, adequate dose and duration) of an antipsychotic agent within the current\n             episode of schizophrenia.\n\n          -  Clinically significant neurological, metabolic (including type 1 diabetes), hepatic,\n             renal, hematological, pulmonary, cardiovascular, gastrointestinal, carcinoma, and/or\n             urological disorder that would pose a risk to the subjects if they were to\n             participate in the study or that might confound the results of the study.\n\n        Note: Active medical conditions that are minor or well-controlled are not exclusionary if\n        they do not affect risk to the subject or the study results. In cases in which the impact\n        of the condition upon risk to the subject or study results is unclear, the Medical Monitor\n        should be consulted. Any subject with a known cardiovascular disease or condition (even if\n        controlled) must be discussed with the Medical Monitor during screening.\n\n          -  Has a history of malignancy < 5 years prior to signing the informed consent.\n\n          -  Clinically significant finding(s) on physical examination determined by the\n             investigator to pose a health concern to the subject while on study.\n\n          -  Clinically relevant abnormal laboratory values or abnormal vital sign\n             values/findings.\n\n        Note: If any laboratory results are outside the normal range, the site may have the\n        subject retested. If upon retesting the value remains outside the normal range, the\n        significance of this value must be discussed with the Medical Monitor for enrollment\n        consideration.\n\n          -  A history or presence of abnormal ECG, which in the investigator's opinion is\n             clinically significant. Abnormal screening ECGs will be centrally over-read, and\n             eligibility will be determined based on the over-read.\n\n          -  Presence or history (within the last year) of a medical or surgical condition (eg,\n             gastrointestinal disease) that might interfere with the absorption, metabolism, or\n             excretion of orally administered lurasidone.\n\n          -  Clinically significant alcohol abuse/dependence or drug abuse/dependence based on\n             DSM-IV-TR criteria within the last 6 months prior to screening.\n\n          -  Positive test results at screening or Baseline for:\n\n               1. Urine drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine,\n                  opiates, phencyclidine, cannabinoids, and methadone). A positive test for\n                  amphetamines, barbiturates, opiates, benzodiazepines or methadone may not result\n                  in exclusion of subjects if the investigator determines that the positive test\n                  is as a result of taking prescription medicine(s) as prescribed. In the event a\n                  subject tests positive for cannabinoids (tetrahydrocannabinol) or alcohol, the\n                  investigator will evaluate the subject's ability to abstain from prohibited\n                  substances during the study. If in the investigator's clinical judgment the\n                  subject will abstain, the subject may be enrolled after consultation with the\n                  Medical Monitor.\n\n               2. Pregnancy test.\n\n          -  Females who are pregnant, lactating, or likely to become pregnant during the study.\n\n          -  Participated in another interventional clinical trial or receiving an investigational\n             product within 30 days prior to randomization.\n\n          -  Donation of whole blood within 60 days prior to randomization.\n\n          -  Known history or presence of clinically significant intolerance to any antipsychotic\n             medications including but not limited to angioedema, serotonin or neuroleptic\n             malignant syndromes.\n\n          -  Clinically relevant history of drug hypersensitivity to lurasidone or any components\n             in the formulation.\n\n          -  Use of concomitant medications that consistently prolong the QT/QTc interval within\n             28 days prior to randomization.\n\n          -  Received depot neuroleptics unless the last injection was at least 1 month or 1\n             treatment cycle prior to screening, whichever is longer.\n\n          -  Received treatment with antidepressants, stimulants, or atomoxetine within 3 days\n             prior to randomization, fluoxetine hydrochloride within 21 days of randomization,\n             monoamine oxidase (MAO) inhibitor within 28 days of randomization, or clozapine\n             within 120 days of randomization.\n\n          -  Use of any antipsychotic medication (other than study drug), carbamazepine,\n             oxcarbazepine, eslicarbazepine acetate, or fluvoxamine, within 3 days prior to\n             randomization (7 days prior to randomization for aripiprazole) and until follow-up.\n\n          -  Has a prolactin concentration \u2265 100 ng/mL at screening, or has a history of pituitary\n             adenoma.\n\n          -  At screening or Baseline the subject answers \"yes\" to \"Suicidal Ideation\" Items 4 or\n             5 on the C-SSRS.\n\n          -  Subject is considered by the investigator to be at imminent risk of suicide or injury\n             to self, others, or property during the study. Subject has a history of one or more\n             serious suicide attempts (based on the investigator's judgment) in the 3 months prior\n             to screening. Subjects determined to be at risk of suicide or injury, as assessed by\n             the investigator at screening, will be referred for further psychiatric evaluation.\n\n          -  Adhering to a special diet for the 28 days prior to drug administration (eg, liquid,\n             protein, raw food diet).\n\n          -  Subject is planning to move during the study, is chronically homeless, or is unable\n             to attend all planned study visits. The Medical Monitor will be consulted for\n             individual cases, as needed.\n\n          -  Demonstrates a decrease (improvement) of > 25% in the PANSS score between screening\n             and Baseline visits.\n\n          -  Subject with newly diagnosed Type 2 diabetes during screening. A subject with Type 2\n             diabetes is eligible for study inclusion if considered clinically stable, which is\n             defined as:\n\n        Random (non-fasting) screening glucose is < 200 mg/dl (11.1 mmol/L); and If \u2265 200 mg/dL\n        (11.1 mmol/L) must be retested in a fasted state. Retested fasted value cannot be \u2265 126\n        mg/dL.\n\n        HbA1c \u2264 6.5%; and If a subject is currently being treated with oral anti-diabetic\n        medication(s), the dose must have been stable for at least 4 weeks prior to screening.\n        Such medication may be adjusted or discontinued during the study, as clinically indicated.\n\n          -  Subject has required hospitalization for diabetes or related complications in the\n             past 12 months.\n\n          -  Subject requires use of concomitant medications that are potent inducers or\n             inhibitors of the cytochrome P450 (CYP) 3A4 enzyme system (Appendix C) from signing\n             informed consent until follow-up.\n\n          -  Clinically significant orthostatic hypotension (ie., a drop in systolic blood\n             pressure of 20 mmHg or more and/or drop in diastolic blood pressure of 10 mmHg or\n             more within 4 minutes of standing up)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": {
            "#text": "249", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01911429", 
            "org_study_id": "D1050301", 
            "secondary_id": "2013-001695-38"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lurasidone 40 mg", 
                "description": "Lurasidone 40 mg once daily", 
                "intervention_name": "Lurasidone 40 mg", 
                "intervention_type": "Drug", 
                "other_name": "Latuda"
            }, 
            {
                "arm_group_label": "Lurasidone 80 mg", 
                "description": "Lurasidone 80 mg once daily", 
                "intervention_name": "Lurasidone 80 mg", 
                "intervention_type": "Drug", 
                "other_name": "Latuda"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo 40 or 80 mg once daily", 
                "intervention_name": "Placebo 40 or 80 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "schizophrenia", 
            "Lurasidone", 
            "Latuda"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "location": [
            {
                "contact": {
                    "email": "nhandal@harmonex.us", 
                    "last_name": "Nelson Handel, MD", 
                    "phone": "334-836-2000"
                }, 
                "facility": {
                    "address": {
                        "city": "Dothan", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "36303"
                    }, 
                    "name": "Harmonex Neuroscience Research"
                }, 
                "investigator": {
                    "last_name": "Nelson Handel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "marina.bussel@prosciencerg.com", 
                    "last_name": "Marina Bussel, MD", 
                    "phone": "424-227-8127"
                }, 
                "facility": {
                    "address": {
                        "city": "Culver City", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90230"
                    }, 
                    "name": "ProScience Research Group"
                }, 
                "investigator": {
                    "last_name": "Marina Bussel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "elizabethrowellmd@diligentclinicaltrials.com", 
                    "last_name": "Elizabeth Zarat-Rowell, MD", 
                    "phone": "562-622-0700"
                }, 
                "facility": {
                    "address": {
                        "city": "Downey", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90241"
                    }, 
                    "name": "Diligent Clinical Trials, Inc"
                }, 
                "investigator": {
                    "last_name": "Elizabeth Zarat-Rowell, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "davidwalling@cnstrial.com", 
                    "last_name": "David Walling, MD", 
                    "phone": "714-799-7799"
                }, 
                "facility": {
                    "address": {
                        "city": "Garden Grove", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92845"
                    }, 
                    "name": "Collaborative Neuroscience Network, LLC"
                }, 
                "investigator": {
                    "last_name": "David Walling, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dchueh@ocresearchtrials.com", 
                    "last_name": "Daniel Chueh, MD", 
                    "phone": "714-289-1100"
                }, 
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92868"
                    }, 
                    "name": "Neuropsychiatric Research Center of Orange County"
                }, 
                "investigator": {
                    "last_name": "Daniel Chueh, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "salma.malik@hhchealth.org", 
                    "last_name": "Salma Malik, MD", 
                    "phone": "860-545-7239"
                }, 
                "facility": {
                    "address": {
                        "city": "Hartford", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06106"
                    }, 
                    "name": "Hartford Hospital"
                }, 
                "investigator": {
                    "last_name": "Salma Malik, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jzaglul@flcrc.com", 
                    "last_name": "Jose Zaglul, MD", 
                    "phone": "941-747-7900"
                }, 
                "facility": {
                    "address": {
                        "city": "Bradenton", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34201"
                    }, 
                    "name": "Florida Clinical Research Center, LLC"
                }, 
                "investigator": {
                    "last_name": "Jose Zaglul, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ok@ehsfamily.com", 
                    "last_name": "Elias Sarkis, MD", 
                    "phone": "352-333-0094"
                }, 
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32607"
                    }, 
                    "name": "Sarkis Clinical Trials - Parent"
                }, 
                "investigator": {
                    "last_name": "Elias Sarkis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "morinadjafi@aol.com", 
                    "last_name": "Morteza Nadjafi, MD", 
                    "phone": "407-423-7149"
                }, 
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32803"
                    }, 
                    "name": "APG Research, LLC"
                }, 
                "investigator": {
                    "last_name": "Morteza Nadjafi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "athebaud@mrgcf.com", 
                    "last_name": "Adly Thebaud, MD", 
                    "phone": "407-330-2262"
                }, 
                "facility": {
                    "address": {
                        "city": "Sanford", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32771"
                    }, 
                    "name": "Medical Research Group of Central Florida"
                }, 
                "investigator": {
                    "last_name": "Adly Thebaud, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "agiorgadze@acmr.org", 
                    "last_name": "Andro Giorgadze, MD", 
                    "phone": "404-881-5800"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "Atlanta Center for Medical Research"
                }, 
                "investigator": {
                    "last_name": "Andro Giorgadze, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "pi@drashrafattalla.com", 
                    "last_name": "Ashraf Attalla, MD", 
                    "phone": "770-319-8025"
                }, 
                "facility": {
                    "address": {
                        "city": "Smyrna", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30080"
                    }, 
                    "name": "Institute for Behavioral Medicine, LLC"
                }, 
                "investigator": {
                    "last_name": "Ashraf Attalla, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "yadalamk@msn.com", 
                    "last_name": "Kashinath Yadalam, MD", 
                    "phone": "337-564-6405"
                }, 
                "facility": {
                    "address": {
                        "city": "Lake Charles", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70629"
                    }, 
                    "name": "Lake Charles Clinical Trials, LLC"
                }, 
                "investigator": {
                    "last_name": "Kashinath Yadalam, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "raman.sanjeev@gmail.com", 
                    "last_name": "Sanjeev Venketraman, MD", 
                    "phone": "248-290-5400"
                }, 
                "facility": {
                    "address": {
                        "city": "Bloomfield Hills", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48302"
                    }, 
                    "name": "Neurobehavioral Medicine Group, PLLC"
                }, 
                "investigator": {
                    "last_name": "Sanjeev Venketraman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sda@flclinical.com", 
                    "last_name": "Sarah Atkinson, MD", 
                    "phone": "585-241-9670"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14618"
                    }, 
                    "name": "Finger Lakes Clinical Research"
                }, 
                "investigator": {
                    "last_name": "Sarah Atkinson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dibuono@rbany.com", 
                    "last_name": "Mark DiBuono, MD", 
                    "phone": "718-317-5522"
                }, 
                "facility": {
                    "address": {
                        "city": "Staten Island", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10312"
                    }, 
                    "name": "Richmond Behavioral Associates"
                }, 
                "investigator": {
                    "last_name": "Mark DiBuono, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "delbelmp@email.uc.edu", 
                    "last_name": "Melissa DelBello, MD", 
                    "phone": "513-245-3415"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "University of Cincinnati Medical Center"
                }, 
                "investigator": {
                    "last_name": "Melissa DelBello, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nora.mcnamara@uhhospitals.org", 
                    "last_name": "Nora McNamara, MD", 
                    "phone": "216-844-5295"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "University Hospitals Case Medical Center"
                }, 
                "investigator": {
                    "last_name": "Nora McNamara, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "wholloway@cuttingedgeresearch.org", 
                    "last_name": "Willis Holloway, MD", 
                    "phone": "405-603-8068"
                }, 
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73116"
                    }, 
                    "name": "Cutting Edge Research Group"
                }, 
                "investigator": {
                    "last_name": "Willis Holloway, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "varmamd@researchmemphis.com", 
                    "last_name": "Anita Varma, MD", 
                    "phone": "901-685-8890"
                }, 
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38119"
                    }, 
                    "name": "Research Strategies of Memphis, LLC"
                }, 
                "investigator": {
                    "last_name": "Anita Varma, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "patel@bbraustin.com", 
                    "last_name": "Divyansu Patel, MD", 
                    "phone": "512-382-6661"
                }, 
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78759"
                    }, 
                    "name": "BioBehavioral Research of Austin"
                }, 
                "investigator": {
                    "last_name": "Divyansu Patel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sbartley@pillarhc.com", 
                    "last_name": "Scott Bartley, MD", 
                    "phone": "214-396-4844"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75243"
                    }, 
                    "name": "Pillar Clinical Research, LLC"
                }, 
                "investigator": {
                    "last_name": "Scott Bartley, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mlucasmd2011@hotmail.com", 
                    "last_name": "Marshall Lucas, MD", 
                    "phone": "281-367-1015"
                }, 
                "facility": {
                    "address": {
                        "city": "The Woodlands", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77381"
                    }, 
                    "name": "Family Psychiatry of The Woodlands, P.A."
                }, 
                "investigator": {
                    "last_name": "Marshall Lucas, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "drmharris@aspclinic.com", 
                    "last_name": "Michael Harris, MD", 
                    "phone": "801-356-5555"
                }, 
                "facility": {
                    "address": {
                        "city": "Orem", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84058"
                    }, 
                    "name": "Aspen Clinical Research"
                }, 
                "investigator": {
                    "last_name": "Michael Harris, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "souad@pspc.org", 
                    "last_name": "Syed Mustafa, MD", 
                    "phone": "425-949-5779"
                }, 
                "facility": {
                    "address": {
                        "city": "Bothell", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98011"
                    }, 
                    "name": "Pacific Institute Of Medical Sciences"
                }, 
                "investigator": {
                    "last_name": "Syed Mufstafa, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "drjmatta@yahoo.com", 
                    "last_name": "Jorge Matta-Gonzalez, MD", 
                    "phone": "787-744-0857"
                }, 
                "facility": {
                    "address": {
                        "city": "Caguas", 
                        "country": "Puerto Rico", 
                        "zip": "00725"
                    }, 
                    "name": "Centro de Investigacion Clinica Psiquiatrica"
                }, 
                "investigator": {
                    "last_name": "Jorge Matta-Gonzalez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicainvestigativa@yahoo.com", 
                    "last_name": "Osvaldo Caro,, MD", 
                    "phone": "787-842-2841"
                }, 
                "facility": {
                    "address": {
                        "city": "Ponce", 
                        "country": "Puerto Rico", 
                        "zip": "00731"
                    }, 
                    "name": "Centro de Investigacion Clinica Psiquiatrica"
                }, 
                "investigator": {
                    "last_name": "Osvaldo Caro, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "yvette_marie_cru@hotmail.com", 
                    "last_name": "Yvette Cruz, MD", 
                    "phone": "787-753-9515"
                }, 
                "facility": {
                    "address": {
                        "city": "San Juan", 
                        "country": "Puerto Rico", 
                        "zip": "00918"
                    }, 
                    "name": "INSPIRA Clinical Research"
                }, 
                "investigator": {
                    "last_name": "Yvette Cruz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A 6-Week Randomized, Parallel, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Evaluate The Efficacy and Safety of Lurasidone in Adolescent Subjects With Schizophrenia", 
        "overall_contact": {
            "last_name": "Medical Director", 
            "phone": "1-866-503-6351"
        }, 
        "overall_official": {
            "affiliation": "Sunovion", 
            "last_name": "Lurasidone Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Ukraine: Ministry of Health", 
                "Italy: The Italian Medicines Agency", 
                "Serbia: Medicines and Medical Devices Agency", 
                "Bulgaria: Bulgarian Drug Agency", 
                "Colombia: National Institutes of Health", 
                "China: Ministry of Health", 
                "Romania: National Medicines Agency", 
                "Spain: Spanish Agency of Medicines", 
                "Korea: Food and Drug Administration", 
                "Malaysia: Ministry of Health", 
                "Philippines : Food and Drug Administration", 
                "Mexico: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary efficacy variable is change from Baseline in the Positive and Negative Syndrome Scale (PANSS) total score at Week 6.", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01911429"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Clinical Global Impression severity (CGI-S) scale at Day 4, Weeks 1, 2, 3, 4, 5, and 6", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Change from Baseline in PANSS total score at Day 4, Weeks 1, 2, 3, 4, and 5", 
                "safety_issue": "No", 
                "time_frame": "5 weeks"
            }, 
            {
                "measure": "Change from Baseline in PANSS positive, negative, general psychopathology, and excitability subscale scores at Day 4, Weeks 1, 2, 3, 4, 5, and 6", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Proportion of responders, where response is based on \u2265 20% improvement from Baseline in PANSS total score at Week 6", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Change from Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) at Week 6", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Change from Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) at Week 6", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Vital signs - will consist of supine systolic and diastolic blood pressures, respiration rate, heart rate, and oral body temperature", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Weight and Waist circumference", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "CogState Computerized Cognitive Test Battery", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Barnes Akathisia Rating Scale (BARS)", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Abnormal Involuntary Movement Scale (AIMS)", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Simpson-Angus Scale (SAS)", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Columbia Suicide Severity Rating Scale (C-SSRS)", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Tanner Staging", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Menstrual Cyclicity - At Baseline, female subjects will be given a calendar to mark the beginning and end of each menses. History of menstrual cyclicity and irregularities will be collected at Visit 1.", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Proportion of remitters, defined as subjects who have score not exceeding 3(mild severity) for items P1, P3, N1, N4, N6, G5 and G9 of the PANSS at Week 6.", 
                "safety_issue": "No", 
                "time_frame": "6 Weeks"
            }
        ], 
        "source": "Sunovion", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sunovion", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}